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Drug Matrix cell A2: Interventions; Generic and cross-cutting issues
S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  Everything you bel ieved about heroin addiction is  wrong (1977). Or biased to an extreme degree by a  vis ion usual ly restricted to the atypical  users  who enter
treatment in societies  where the drug is  i l legal , hard to obtain and demonised. In the 1970s  a  high proportion of US soldiers  became addicted in Vietnam but (even
if they sti l l  dabbled) ‘recovered’ without treatment on return to the USA, highl ighting the importance of environment and the rewards  of a  ‘normal ’ l i fe; those for
whom this  i s  not enough or who cannot access  these rewards  face problems other than their substance use.
S  ‘Pre-recovery’ foundations  of recovery orientation (2000). Though relatively recent, justi fication for the ‘seminal ’ tag is  that this  study predated by many years
the recovery era in Bri tish pol icy, but la id some of the foundations  for i ts  shi ft in emphasis  from the psychological  or biochemical  grip of addiction to l i festyle
change which breaks  with the past satis fyingly enough to forge a pos itive, non-addict identi ty and prevent relapse.
K  Remiss ion is  the norm but some take much longer than others  (2011). US national  population survey found that ten years  after meeting cri teria  for dependence,
in respect of cannabis  two thirds  were no longer dependent and three quarters  for cocaine. Reanalys is  (2013) of data from the same series  of surveys  points  out
most remit without treatment and that s ince onset is  typical ly around age 20, by age 30 most people formerly dependent on cannabis  or cocaine are no longer
dependent.
K  Engl ish treatment services  vindicated (1999). NTORS which recruited i ts  sample in 1995 remains  the most important treatment study in Bri ta in. Conducted when
al l  the treatment modal i ties  i t s tudied (inpatient, res identia l  and methadone) were under pol i tical  and/or financial  threat, i t seemed to show they reaped benefi ts
which greatly outweighed their costs . Recruiting i ts  sample about eleven years  later, DTORS (2009) reached s imi lar conclus ions, but nearly three quarters  of the
sample could not be fol lowed up.
K  Abstinence rare outcome in Scotland (2006). Recruiting i ts  sample in 2001, DORIS was  the Scottish equivalent to the Engl ish NTORS and DTORS. The apparent
mismatch between the abstinence ambitions  of the patients  and the lack of abstinence outcomes was the main theme, but the findings  were not so clear cut. See
also these reports  from DORIS on employment (2008) and crime (2007) outcomes, and an omnibus  report (2008) on the project’s  findings.
K  Influentia l  treatment process  model  emerges  from US studies  (2002). DATOS was one of the US equivalents  to the Scottish DORIS and the Engl ish NTORS and
DTORS studies . Instead of heroin, cocaine was the main drug. For the UK the study’s  s igni ficance lay less  in i ts  outcomes, than in the highly influentia l  model  of
how treatment works  and therefore how i t can be improved which emerged from this  and other studies  by the same US research insti tute.
K  Motivating aftercare (2007). US inpatient treatment centre systematical ly appl ied s imple prompts  and motivators  to substantia l ly improve aftercare attendance
and sustain recovery. See also later report from same study.
R  Substantia l  annual  rate of remiss ion from dependence on i l legal  drugs  (2010). Synthes is  of treatment and general  population studies  helps  fi l l  the gap in the key
study above relating to dependence on opiate-type drugs; each year one or two patients  out of every ten overcome their dependence. For amphetamines
corresponding figure was from one in two to one in s ix, and for cocaine from one in eight to one in twenty.
R  Remiss ion is  the norm (2010). In the general  population and in treatment samples , on average studies  have found hal f (or more in recent studies) of a l l  problem
substance users  were later in remiss ion. After treatment, s ix out ten remitted by becoming abstinent, but among general  population samples , s ix out of ten
continued to use.
R  Engaging the treatment-res istant (2010). Confrontation and tough love are not the best ways  for fami l ies  to persuade their problem drug users  to get help.
R  Tai lor induction (2005). Some patients  need motivation bolstered and options  explored, for others  this  i s  not just unnecessary but counterproductive.
R  Chronic care for chronic conditions  (2009). General ly the offer of long-term continuing care or ‘aftercare’ leads  to better outcomes; the impl ication for this  US
expert reviewer is  that dependence is  best treated as  a  chronic condition. A later review (2014) bui l t on his  work, adding 13 studies  to the 20 previous ly identi fied
and aggregating a l l  substance use outcomes reported in the tria ls . The result was  a  less  pos itive picture than the previous  review’s  count of studies  which found at
least one measure enhanced by continuing care.
G  Recovery defined (2008). In 2008 a national  UK chari ty a iming to foster evidence-based debate about drug pol icy brought together 16 experts  to (i f they could)
agree an understanding of ‘recovery’ from problem substance use. Remarkably, they did agree, characteris ing i t as  “voluntari ly-sustained control  over substance
use which maximises  health and wel lbeing and participation in the rights , roles  and responsibi l i ties  of society”.
G  Treatment principles  ([US] National  Insti tute on Drug Abuse, 2012). Presents  13 research-based principles  of addiction treatment, seven of which have been
tested against the North American evidence. Principles  relating to individual is ing treatment were cons istently supported.
G  Strategies  to promote continuing care (2009). Expert US consensus  on practical  s trategies  to promote continuing care based on review above.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page or hot topics  on promoting recovery through employment, on mutual  a id and user-involvement, the need for res identia l
care, on individual is ing treatment, and on recovery as  a  treatment objective.
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What is this cell about? Whether medical or psychosocial, chosen positively or under pressure, patients have to decide to get help, find
their way to treatment or get sent there. Decisions must be made about treatment objectives and the form, intensity and duration of care,
relationships forged, and attention paid to psychological problems and social circumstances which affect the chances of a sustained end
to dependent substance use. Seen as important is the very fact that someone or some institution sanctioned by society has identified the
patient/client as in need and deserving of help, believes they will benefit, and has the status of an expert in the problem and its
solutions. This cell is about these generic functions and ‘common factors’, now widely recognised as at least as important as the
particular therapy. Also here we touch on the nature of addiction and the nature of the caseload seen in treatment services, helping place
those services in the context of the spectrum of dependent drug use in society and the ‘natural’ processes of recovery which treatment
seeks to harness and accelerate.
Where should I start? Perhaps at the end, with what treatment should be trying to achieve. Inevitably that ‘should’ word plunges us in to
the worlds of value and politics not susceptible to resolution via randomised controlled trial. Our interest in this course is not to even try
for a resolution, but to learn at least two lessons: how those worlds sometimes very directly generate research in the expectation that the
results will help further those agendas; and how those worlds influence the research itself, which like every other intentional human
action, is a motivated endeavour; science is never just about science.
The governments of the UK agree that above all what they want out of treatment is ‘recovery’. What they mean by that is not spelt out,
but the broad themes are clear: some of the most marginal, damaged and unconventional of people are to become variously abstinent
from illegal drugs and/or free of dependence and (as Scotland’s strategy put it) “active and contributing member[s] of society”, echoing
governmental ambitions in England dating back to the mid-2000s for more drug users to leave treatment, come off benefits, and get back
to work, becoming an economic asset rather than a drain.
Do experts and the people on the ground see it the same way? In 2008 the non-governmental UK Drug Policy Commission brought 16
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together to thrash it out. They couldn’t agree what being recovered was, but did agree that getting recovered is “characterised by
voluntarily-sustained control over substance use which maximises health and wellbeing and participation in the rights, roles and
responsibilities of society.” Their brief report expands on each element of the definition. Note that by ‘control’ they meant “comfortable
and sustained freedom from compulsion to use” – the traditional treatment goal of ending addiction. But that was, they said, not enough.
Recovery is not just about ending pathology, but “accrual of positive benefits ... a satisfying and meaningful life”.
Note what is not in their definition. Abstinence is missing. So too is leaving treatment, a rejection of what for government dating back to
2005 was the starting point of their emphasis on social reintegration which morphed in to recovery – the need to move patients through
and out of the treatment system to free up slots in what was clearly going to be a less resource-rich era. Another government ambition
was to get ex-patients back to work, and that the commission’s 16 accepted, but in a softer formulation which allowed for other routes to
a meaningful and productive life. This then is the agenda for the UK’s recovery era – or at least, the most worked out version we have.
Highlighted study Burned in to the memory of participants in the UK drugs field in the mid-90s is the National Treatment Outcome
Research Study, better known by its acronym NTORS (pronounced ‘entors’). It was succeeded but not superseded by DTORS and in
Scotland, DORIS, and remains the most important treatment study ever conducted in the UK. It also exemplifies two lessons for this ‘bite’:
that research is generated in order to support or challenge politics and values; and how that research is conducted and presented is
affected by (perhaps a different set of) politics and values.
The study was spawned by a task force set up in 1994 by Dr Brian Mawhinney, a UK health minister who saw his mission as infusing
biblical values in public life. It was his challenge the task force’s chair Reverend John Polkinghorne was alluding to when he said the
impetus for his review included concern that “treatment might often be insufficiently oriented towards the attainment of abstinence.
More specifically ... there were those who questioned the acceptability and legitimacy of methadone maintenance programmes, which
seemed to some simply to replace an illegal drug with a similar drug legally prescribed” – sentiments strikingly similar to those
expressed by the current UK government.
Suspicious of ‘expert’ opinion, Mawhinney had condemned the “‘drug industry’ who resist any threat to their present autonomy.”
Ironically, his review commissioned its key research project from the heart of that industry, the National Addiction Centre, whose allied
health services provided the treatments he questioned. The questionable, headline-grabbing ‘£3 in social benefits for £1 spent in
treatment’ extrapolation from that study will be dealt with in cell E2. For the moment we record that while acknowledging room for
improvement, it vindicated all the treatment modalities it studied (inpatient, residential and methadone), described by the researchers as
a “powerful national asset”. Yet with no control group of non-treated problem drug users, the improvements it documented could not be
(but effectively were) wholly attributed to the treatment episodes on which the study focused. That was the major if perhaps unavoidable
weakness in the study, but there were others (see the linked report), including some which make sense as a protective tactic. Highly
political, the genesis of the study was an attack on the drug treatment sector, and the study itself can be seen as that sector fighting
back. But like many essentially well designed studies, almost despite the agendas involved, lessons emerged which none of the parties
to the endeavour would have wanted or predicted.
Issues to think about
 A new life – or just the ending of addiction? With the desired ‘recovery’ outcome defined, let’s work backwards to what that means for
treatment. Logic dictates it should determine how to assess success and the inputs needed to achieve it. Some argue that inputs related
to non-addiction elements like wellbeing and reintegration are not essential to the treatment of addiction, but the business of other
welfare, employment and health services. The UK group which defined recovery did not let treatment off so lightly. Their definition was,
they said, about “the goals of treatment and rehabilitation ... that could be applied to all individuals tackling problems with substance
misuse, and all services helping them.”
Take that seriously, and surely it means treatment services will need to gear up with integrated access to vocational experts, family re-
unification inputs, artistic and creative opportunities, and whatever else for their patients is needed to move towards a meaningful and
productive life. Pause and shift ground from illegal drugs to tobacco or alcohol. Would we say someone who has sustainably stopped
smoking or drinking, but hasn’t found a job, is still on benefits, maybe even offending, and who remains at a loss for meaning in life, has
failed to recover from their addiction?
But perhaps there are good reasons why these wider issues intrude for socially unacceptable addictions like heroin and cocaine, in a way
they don’t for drinking and smoking. By the time you have narrowed down to the minority who try these drugs, the very few who become
regular users, those of the former who become clinically dependent, and then the subset of those who want to stop but can’t without
treatment, then you have selected a highly atypical and usually multiply and deeply troubled population – the caseload of addiction
treatment services.
When a broader cross-section of young men is liberally sprinkled with heroin in an environment devoid of other interests and normal ties,
the more deviant and drug-experienced among them may use regularly, but on return to their normal environments, all but a few will
cease regular use and stay that way without ever having received any substantive treatment. These were the totally unexpected
observations of Lee Robins and colleagues commissioned by the US government to investigate the looming avalanche of ex-military
heroin addicts created by the Vietnam war. That avalanche never materialised, and the returnees barely troubled US treatment services.
However, the few who did resort to treatment exhibited the classic pattern of multiple problems and post-treatment relapse.
Reflecting on the implications, Robins argued that “drug users who appear for treatment have special problems that will not be solved by
just getting them off drugs.” For her the reason why relapse is the norm after treatment seemed obvious: “It is small wonder that our
treatment results have not been more impressive, when they have focused so narrowly on only one part of the problem.” From the 1970s
then comes this strong argument for what today we might call a recovery orientation in services treating addiction to drugs like (in terms
of their social as well as pharmacological properties) heroin; that for these addicts, their drug use is entangled with social dislocation
and multiple problems, which unless addressed will repeatedly precipitate them back in to addiction.
Now you may be in a better position to ask yourself: Should we accept repeated and widespread post-treatment relapse as a sign of the
intractability (or as US guidelines have it, the persistence of drug-induced brain dysfunction) of addiction, or is it a sign of the inadequacy
and mistargeting of treatment? If treatment takes on the recovery challenge, how many fewer patients will we be able to afford to treat,
and will that be counterbalanced by greater success in closing the revolving door of treatment re-entry due to relapse? Is it simply beyond
the reach of any feasible treatment service, even with partner services, to create environmental changes of the magnitude which led to
rapid, widespread and lasting remission from dependence among Vietnam returnees? Must we set our sights lower, and ameliorate while
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we seek usually only slightly to accelerate the normal processes of remission (tracked in these studies: 1 2 3) – or is that what could
prove a self-fulfilling lack of ambition?
 What do the patients want? In the era of the consumer model of health service delivery, allusion to the primacy of the patient’s wishes
is required in any policy statement or guidelines. That makes those wishes contested territory; commentators committed to certain
treatment goals will appeal for validation to what is seen as the ultimate authority – the patient. In turn that makes research on patient
perspectives critical, and sometimes too contested.
The prime example comes from Scotland, where researchers from the DORIS national treatment evaluation study differed over the
implications of their findings. It started with the “surprising” finding that 57% of Scottish drug treatment clients selected abstinence as
their sole goal for changing their drug use, seemingly the first time any large-scale British research project had asked this fundamental
question. For the lead author the answers were a sign that we have failed to match patients’ ambitions and instead prioritised harm
reduction. Rather than the reservations expressed in the scientific paper, he said “The drug users in the Scottish research have spoken
with admirable clarity.” But armed with further, more in-depth findings from England, later a former DORIS colleague disagreed. It was,
she said, unclear what patients meant when they ticked “abstinence/drug free” in response to the question, “What changes in your drug
use do you hope to achieve by coming to this agency?” Did they mean free from all drugs, or just the one(s) causing them problems? Free
now or in the future? An aspiration rather than what even the patient would see as a realistic goal? It might also be asked whether the
finding really was “surprising”; 44% were starting drug-free and/or explicitly abstinence-based treatments and the same proportion were
in prison, where abstinence would normally have been the only sensible objective. Rather than a surprising mismatch, the paper can as
easily be read as showing patients’ objectives match those of the treatment they are entering and the constraints of the setting.
Still, the seeming contrast with the supposed finding that just 3% of Scottish methadone patients emerged from treatment drug-free was
headlined as proving treatment fails patients, and used by politicians to justify what the media described as a “Cold turkey plan for Scots
addicts.” Their case was sharpened by the further contrast with what was portrayed as a corresponding figure of 25% in England.
All this was sloppy at best, deliberately misleading at worst. The iconic ‘3%’ figure came from a DORIS report. Read our analysis, and you
will see that it was based on patients who had entered methadone programmes only after leaving their first treatment during the study
period. The corresponding figure for England instead (and more conventionally) related to the initial treatment. Also, the definition of
abstinence in Scotland meant patients must not be using any illegal drug and not on methadone. In England, they could have been on
methadone and using cannabis. Scottish apples were being compared with English pears, and then with the supposed ambitions of
Scottish patients, which in reality were not at all clear.
Was this a case of science being bent to agendas? And even if it was, did it highlight a valid point about insufficient attention to patient
wishes and whole-life recovery in Scottish services? As we point out in a hot topic entry, though important, misreading of the DORIS
findings should not obscure the fact that, however the individual defines it, stopping use of some drugs (especially use so problematic
that it has driven them to seek help) is a common long-term goal, and that for substitute prescribing patients, it often extends to
eventually being free of legal substitutes too.
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